Washington Univ. v. William J. Catalona

490 F.3d 667
CourtCourt of Appeals for the Eighth Circuit
DecidedJune 20, 2007
Docket06-2286, 06-2301
StatusPublished
Cited by1 cases

This text of 490 F.3d 667 (Washington Univ. v. William J. Catalona) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Washington Univ. v. William J. Catalona, 490 F.3d 667 (8th Cir. 2007).

Opinion

RILEY, Circuit Judge.

We are asked to determine the ownership of biological materials contributed by individuals for the purpose of genetic cancer research and currently housed on the campus of Washington University (WU). WU brought a declaratory judgment action against Dr. William Catalona (Dr. Catalona), a former WU medical school faculty member, seeking to establish WU’s ownership of the research biological materials. Dr. Catalona counterclaimed, seeking a declaration the contributing individuals could direct the transfer of their biological materials to him. Dr. Catalona also moved for an order prohibiting WU from utilizing, disseminating, transferring, or destroying the biological materials at issue. The district court 1 concluded WU owns the biological materials and neither Dr. Catalona nor any contributing individual has any ownership or proprietary interest in the disputed biological materials. These appeals followed. We affirm.

I. BACKGROUND

WU, a prominent private research university located in St. Louis, Missouri, houses its own medical school, including a Division of Urologic Surgery (Division). Within the Division, WU physicians treat patients, teach students and residents, and conduct medical research on urologic diseases such as prostate cancer. Dr. Ca-talona, a highly respected urologist and urologic surgeon and researcher, was employed by WU from 1976 to 2003, and he served as Division Chief from 1984 to 1998. During Dr. Catalona’s tenure at WU, he performed thousands of surgeries, many involving prostate cancer. As a leading medical researcher for WU, one of Dr. Catalona’s principal areas of research was the genetic basis of prostate cancer. In 1983, Dr. Catalona began collecting samples of biological materials, such as blood and tissue removed during surgery, to be used later for prostate cancer research. Dr. Catalona encouraged his colleagues to do the same.

Dr. Catalona was instrumental in establishing the GU 2 Biorepository (Bioreposi-tory), the world’s largest storage facility for biological samples collected by Dr. Ca-talona and other WU physicians for prostate cancer research. The Biorepository is housed in one or more buildings owned by WU. WU provides the majority of funding necessary to support the maintenance and operation of the Biorepository. Additional funding is provided by public and private grants payable to and administered by WU as the “grantee.” While employed by WU, Dr. Catalona raised several million dollars in outside funding for the Biorepo-sitory. Other WU employees, including Dr. Catalona’s successor as Division Chief, also have raised a substantial amount of funds.

During the relevant time period, Dr. Catalona and other Division physicians performed many genetic cancer research studies, with each study naming a particu *671 lar WU physician as the “principal investigator,” a term designating the person “in charge of conducting the research protocol.” Regardless of the physician designated as principal investigator on a particular research study, the named principal investigator generally collaborated with several other individuals in the research studies.

In order to conduct these studies, individuals were invited to participate in genetic research. Individuals who chose to donate excised prostate tissue or a blood sample to medical research and to become a research participant (RP) were required to complete an informed consent form. 3 Although the language of the consent forms differs, depending upon the nature of the particular study or the study’s principal investigator, generally all of the forms contain similar provisions, such as the WU Medical Center or WU School of Medicine logo, the principal investigator, the purpose of the research, and the nature of the RP’s participation.

The consent forms often used the term “donation” to describe the biological sample’s transfer from the RP to a WU physician or medical technician. The forms also noted biological samples “may be used for research with our collaborators at [WU], other institutions, or companies.” The consent forms typically provided that by participating in the study, the RP “agree[s] to waive any claim [he] might have to the body tissues that [he] donate[s]” and also “waive[s] the right to any new material or process developed through research involving [his] tissues.” RPs also were informed by the consent forms, “Your participation is voluntary and you may choose not to participate in this research study or withdraw your consent at any time.” Some consent forms indicated RPs could request destruction of their biological materials if they changed their minds about participating in the study, but noted it would not be possible to destroy or recall any research results already obtained. Other consent forms made no mention about an RP’s right to request destruction of materials donated to research. 4

In addition to the consent form, RPs received a genetic research information brochure (brochure) to review and sign. The brochure provided RPs’ tissue samples (1) will be used by “[WU] Medical Center researchers,” (2) “may be shared with other authorized researchers doing research in similar fields at [WU] and other research centers,” and (3) “may be used for studies currently in progress or studies conducted 10 or 20 years from now.” Similar to the consent forms, the brochure used the term “donation” to describe the RP’s participation, noting, “By agreeing to participate, you are making a free and generous gift of your tissue to research that may benefit society.” The brochure advised RPs, “You will receive no monetary payment for your tissue nor can you claim ownership rights to any medical or scientific product that results from research with your tissue.” The brochure also informed RPs of their right to have their biological materials destroyed upon request should they change their minds about participating in the research study.

At the time of the district court’s permanent injunction hearing in this case, more than 30,000 RPs were enrolled in WU prostate cancer research studies. About 2,500 to 3,000 RPs had been patients of Dr. Catalona. The Biorepository contains: *672 (1) approximately 3,500 prostate tissue samples taken from patients of Dr. Catalo-na and other WU physicians within the Division; (2) about 100,000 blood or serum samples donated by over 28,000 men, 75% of whom were not patients of any WU physician, but rather were volunteers recruited through the media; and (3) DNA samples provided by approximately 4,400 men, which included patients of different WU physicians and relatives of those patients.

Over the years, other research institutions requested and received biological samples from the Biorepository to conduct genetic cancer research projects either in partnership with or independent of WU. While at WU, Dr. Catalona repeatedly transferred Biorepository materials to other research institutions pursuant to material transfer agreements (MTAs). The MTAs typically were signed by an authorized WU official as well as a providing investigator. Several MTAs personally signed by Dr. Catalona, as the principal or providing investigator, acknowledge WU as the owner of the biological samples.

In early 2003, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
490 F.3d 667, Counsel Stack Legal Research, https://law.counselstack.com/opinion/washington-univ-v-william-j-catalona-ca8-2007.